10 Reflexiones sobre Menopausia, Climaterio y Terapia Hormonal, Bibliografía

Bibliografía terapia hormonal

Dr. Álvaro Monterrosa Castro, M.D

  1. The practice Committee of the American Society for Reproductive Medicine. Estrogen and Progestogen therapy in postmenopausal women. Fertil Steril. 2004; 82(1):S70-S80.
  2. Shoham Z, Kopernik G. Tools for making correct decision regarding hormone therapy. Part I. Background and drugs. Fertil Steril. 2004; 81(6):1447-1457.
  3. Monterrosa A. ¿La Terapia hormonal, sigue siendo valida? Controversias en Ginecología y Obstetricia. 2004; 12(67):1571-1575.
  4. North American Menopause Society. Position Statement. Estrogen and Progestogen use in peri and postmenopausal women: October 2004; en prensa.
  5. Fremont-Smith M, ;Eigs JV, Graham RM, et al. cancer of endometrium and prolonged estrogen therapy. JAMA.1946; 31:805-808.
  6. Barrett-Connor E, Solne S, Greendale G, et al. The postmenopausal estrogen / progestin interventions study; primary outcomes in adherent women. Maturitas. 1997; 27: 261-274.
  7. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen /progestin regimens on heart disease risk factor in postmenopausal women. The Postmenopausal estrogen / progestin Intervention (PEPI) Trial. JAMA. 1995; 273:199-208.
  8. Greendale GA, Wells Bradley, Marcus R, et al. How Many women loss bone mineral density while taking hormone replacement therapy? Result from the Postmenopausal estrogen / progestin Intervention (PEPI) Trial. Arch Intern Med. 2000; 160:3065-3071.
  9. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial Histology in postmenopausal Women. The Postmenopausal estrogen / progestin Intervention (PEPI) Trial. JAMA. 1996; 275(5):370-375.
  10. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on bone mineral density. Result from the Postmenopausal estrogen / progestin Intervention (PEPI) Trial. JAMA 1996. 1996; 276:1389-1396
  11. Greendale G, Espeland M, Slone S, et al. Bone Mass Response to discontinuation of long-term hormone replacement therapy. Results from the postmenopausal estrogen / progestin interventions (PEPI) safety follow-up study. Arch. Intern Med. 2002; 162:665-672.
  12. Skouby SO. Climacteric medicine. European Menopause and Andropause society (EMAS) statements on postmenopausal hormonal therapy. Maturitas. 2004; 48: 19-25.
  13. Bakken K, Alsaker E, Eggen A, et al. Hormone replacement therapy and incidence of hormone – dependent cancer in the Norwegian women and cancer study. Int J. cancer. 2004; 112:130-134.
  14. Federación Latinoamericana de Sociedades de climaterio y menopausia. (FLASCYM). Consenso Latino Americano sober terapia hormonal de reemplazo en postmenopausia. Salta. Argentina. 2004: In prensa.
  15. Position Statement en reunión de consenso. Posición Latinoamericana sobre el estado actual de la terapia hormonal. Bahía. Brazil. 2004. In-prensa.
  16. Naftolin F, Schneider HPG, Sturdee DW. The writing Group of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Position statement by the executive committee of the International Menopause Society. Revised October 2004. Climacteric; 2004; 7:333-337.
  17. Colditz GA, Hankinson SE, Hunter DJ. The use of estrogen and progestin and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995; 332:1589-1593.
  18. Writing Group for the Women´s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women´s Health Initiative Randomized controlled trial. JAMA. 2002; 288:321-333.
  19. The Women´s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women´s Health Initiative Randomized Controlled Trial. JAMA. 2004; 291(14):1701-1712.
  20. Bundred NJ. Breast cancer and HRT use. Maturitas. 2004; 49:S3-S4.
  21. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer. A clinician´s view. Maturitas. 2004; 49:51-57.
  22. Martínez G. Terapia hormonal de reemplazo y cáncer. Rev. Colombiana de Obstetricia y Ginecología 2004; 55(1): 40-59.
  23. Hulley S, Grady D, Bush T, et al. Randomized Trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998; 280:605-613.
  24. Hulley S, Furberg C, Barret-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen / progestin replacement study. Follow-up. (HERS II). JAMA. 2002; 288:58-66.
  25. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen / progestin replacement study. Follow-up. (HERS II). JAMA. 2002; 288:49-57.
  26. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288:872-881.
  27. Uthian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxiprogesterone acetate. Fertil Steril. 2001; 75:1065-1079.
  28. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxiprogesterone acetate on endometrial bleeding. Fertil Steril 2001; 75:1080-1087.
  29. Pickar JH, Tien Yeh I, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxiprogesterone acetate. Fertil Steril 2001; 76:25-31
  30. Pickar JH, Tien Yeh I, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxiprogesterone acetate. Two-year sub study results. Fertil Steril 2003; 80(5):1234-1240.
  31. Lobo RA, Bush T, Carr BR, et al. Effects of lower doses of conjugated equine estrogens and medroxiprogesterone acetate on plasma lipids and lipoproteins, coagulation factors and carbohydrate metabolism. Fertil Steril. 2001; 76:13-24.
  32. Lindsay R, Gallagher JC, Leerekoper M, et al. Effects of lower doses of conjugated equine estrogens with and without medroxiprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
  33. Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpregnane progestin. Gynecol Endocrinol. 1999; 13:316-326.
  34. Rubing A. Drospirenona: A new cardiovascular active progestin with antialdosterone and antiandrogenic properties. Climacteric. 2003;6(suppl3):49-54.
  35. Byrjalsen I, Bjarnason N, Christiansen C. Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy. Am J Obstet Gynecol 1999; 180:539-549.
  36. Suvanto-Lukkonen E, Sundstrom H, Pentinnen j, et al. Percutaneous estradiol gel with an intrauterine releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997; 26:211-217
  37. The Practice Committee of the American Society for Reproductive Medicine. The menopausal transition. Fertil Steril. 2004; 82(Suppl-1):S107-S110.
  38. Mosca, Appel L, Benjamín E, et al. Evidence-Based Guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672–693
  39. Gómez G, Onatra W, Sánchez F. Climaterio y Menopausia. 2004. Cali.
  40. Monterrosa A. 1500 recomendaciones y aseveraciones nutricionales para las mujeres en Menopausia. 2004; In prensa.
  41. Monterrosa A, Peñaloza P, Arteaga ME. Cuantificación del calcio presente en la dieta que consumen Mujeres entre 45 y 55 años de edad, residentes en Cartagena, Colombia. Rev. Colombiana de Menopausia. 2003: 9(3):213-223.
  42. MC tiernan A, Kooperberg C, White E, et al. Recreational Physical Activity and the risk of breast cancer in postmenopausal women. The Women´s Health Initiative Cohort Studt. JAMA. 2003; 290:1331-1336.
  43. Manson JE, Greenland P, La Croix AZ. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl L Med. 2002: 347 (10):716- 724.
  44. Kopernik G, Shoham Z. Tools for making correct decisions regarding hormone therapy. Part II. Organ response and clinical applications. Fertil Steril. 2004; 81(6):1458-1477.
  45. North American Menopause Society. NAMS. Position Statement. Treatment of menopause associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause. 2004; 11(1):11-33.
  46. Avis NE, Crawford SL, McKinlay SM. Psychosocial, behavioral and health factor related to menopause symptomatology. Women´s Health. 1997; 3:103-120.
  47. Gold EB, Sternfeld B, Kelsey JL. Et al. Relation of demographic and lifestyle factor to symptoms in a multi racial ethnic population of women 40-55 years of age. Am J Epidemiol 2000; 152: 463-473.
  48. Randolph JF, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition relationship to ethnicity, body size and menopausal status. J Clin Endocrinol Metab. 2003; 88:1516 – 1522.
  49. Taffe J, Garamszegi C, Dudley E, et al. Determinants of self rated menopause status: Maturitas 1997; 27:223-229.
  50. Dudley EC, Hopper JL, Taffe J, et al. Using longitudinal date to define the perimenopause by menstrual cycle. Characteristics. Climacteric 1998; 1:18-25.
  51. Guthrie JR, Dennerstein L, Hopper JL, et al. Hot flushes, menstrual status and hormone levels in a population based sample of midlife women. Obstet Gynecol 1996; 88:437-442.
  52. Dennerstein L, Dudley E, Burger H, et al. Well-being and the menopausal transition. J.Psychosom Obstet Gynecol 1997; 8:95-101.
  53. Guthrie JR, Ebeling PR, Hoper JL, et al A prospective study of bone loss in menopausal Australian-born women. Osteoporosis Int. 1998; 8:282-290.
  54. Shulman Lee, Harari D. Low dose transdermal estradiol for symptomatic perimenopause. Maturitas. 2204; 11(1):34-39.
  55. Stearns V, Ullmer L, Lopez J, et al. Hot flushes. Lancet 2002; 360:1851-1861.
  56. Anderson G, Judd W, Kauntz A. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women´s health initiative randomized trial. JAMA. 2003; 290:1739-1748
  57. Molnar GW, Body temperatures during menopausal hot flashes. J Appl Physiol. 1975; 38: 499-503.
  58. Kromberg F, Barnard RM. Modulation of menopausal hot flashes by ambient temperature. J Therm Biol. 1992; 17:43-49.
  59. North American Menopause Society. Position Statement. Estrogen and Progestogen use in peri and postmenopausal women: September 20003. Menopause. 2003; 10(6):497-506.
  60. Mac Lennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes (Cochrane Review. Cochrane database Syst Rev. 2001; 1. CD002978.
  61. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet. 2000; 356: 2059 – 2063.
  62. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998; 16:495-500.
  63. Conclusions of the 2nd European consensus meeting on menopause. 2003. Athens, Greece. Menopause Review 2003; 8(2):1-7.
  64. www. escalacervantes.com
  65. North American Menopause Society. Position Statement. Estrogen and Progestogen use in peri and postmenopausal women: October 20002. Menopause. 2003; 10(6):6-12.
  66. Schneider HPG, Pines A, O´neil S, et al. International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Position statement by the executive committee of the International Menopause Society. Climacteric. 2004; 7:8-11.
  67. American College of Obstetricians and Gynecologists (ACOG). Issues state of the art guide to hormone therapy. Obstet Gynecology. 20004. In prensa.
  68. Lobo R. Views on recent trials and the future of hormonal therapy. Clinical Obstetrics and Gynecology 2004; 47(2):424-427.
  69. Cauley JA, Robbins J, chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women´s health initiative randomized trial. JAMA. 2003; 209:1729-1738.
  70. Siris E, Miller P, Barret-Connor E, et al. Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women: Results From the National Osteoporosis Risk Assessment (NORA) JAMA. 2001; 286: 2815-2822.
  71. Banks E, Beral V, Reeves G. Fracture incidence in relation to the pattern of use hormone therapy in postmenopausal women. JAMA. 2004; 291:2212-2220
  72. La terapia hormonal sustitutiva es beneficiosa en mujeres postmenopausicas con arthritis reumatoide. J Rheumatology 2003; 7:1456-1463.
  73. Greenspan SI, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronato for prevention of bone loss in elderly women. A randomized controlled trial. JAMA. 2003; 289:2552-2533.
  74. Chlebowski R, Wactawski-Wende J, RitenBaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N. Engl J Med. 2004; 350:991-1004.
  75. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002; 288:334-341.
  76. Wise PM, Dubal DB, Wilson ME, et al. Estrogens: trophics and protective factors in the adult brain. Front Neuroendocrinol 2001; 22:33-66.
  77. Diaz Brinton R, Chen S, Montoya A, et al. The Women´s health initiative estrogen replacement therapy is neurotrophic and neuroprotective. Neurobiol Aging 2000; 21:475-496.
  78. Skoog I, Gustafson D. HRT and dementia. J. Epidemiol Biostat. 1999; 4:227-251.
  79. Henderson VW, Guthrie JR, Dudley Ec, et al. Estrogen exposures and memory at midlife. A population based study of women. Neurology. 2003; 60:1369-1371.
  80. Grodstein F, Stamper M, Manson J, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Eng J Med. 1996; 335: 453-461.
  81. Miech RA, Breitner JC, Zandi PP, et al. Incidence of AD may decline in the early 90s for men, later for women. The Cache County Study. Neurology 2002; 58:209-218.
  82. Zandi PP, Carlson MC, Plassman BL, et al Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County Study. JAMA. 2002; 288:2123-2129.
  83. Breitner JC, Wyse BW, Anthony JC, et al. APOE-4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 1999; 53:321-331.
  84. Kawas C, Resnick S, Morrison A, et al. Un estudio prospectivo de terapia de reemplazo hormonal y riesgo de desarrollar enfermedad de Alzheimer. El estudio Longitudinal de envejecimiento de Baltimore. (Versión en español). Neurology 1997; 48:1517-1521.
  85. Shumaker S, Legault C, Rapp S, et al. Estrogen plus progestin and the incidence of dementia and lid cognitive impairment in postmenopausal women. The Women´s health initiative Memory Study. A randomized controlled Trial. JAMA. 2003; 289:2651-2662.
  86. Maskchak CA, Lobo RA, Dozono-takano R, et al. Comparison of pharmacodynamic properties of various estrogens formulations. Am J Obstet Gynecol. 1982; 144:511-518.
  87. Shumaker S, Legaulth C, Kuller L. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women´s Health Initiative Memory study. JAMA. 2004; 291(24):2947-2958.
  88. Espeland MA, Rapp SR, Shumaker SA, et al Conjugated equine estrogens and global cognitive function in postmenopausal women. Women´s Health Initiative Memory Study. JAMA. 2004; 291:2959-2968.
  89. Grady D, Yaffe K, Kristof M, et al. Effects of postmenopausal hormone therapy on cognitive function: The Heart and estrogen / progestin replacement study. Am J. Med. 2002; 113:543-548.
  90. Breteler MM, Claus JJ, Grobbee De, et al. Cardiovascular disease and distribution cognitive function in elderly people: The Rotterdam Study. BMJ. 1994; 308:1604 – 1608.
  91. Herrington DM, Reboussin DM, Brosnihan B, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 2000; 343:522-529.
  92. Naftolin F, Taylor H, Karas R, et al. The women’s health initiative could not have detected cardio protective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004; 81(6):1498-1501.
  93. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women. Arch Intern Med. 2004; 168:482-484.
  94. Lethaby AE, Coocke I, Ross M. Progesterone / Progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. The Cochrane Library 2002. Issue 2.
  95. Jensen J. Noncontraceptives applications of the levonorgestrel intrauterine systems. Current Women Health Report. 2002; 2:417-422
  96. Wathen CN, Feig DS, Feightner JW, et al. Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task force on Prevention Health. Care Can. Med. Assoc. J. 2004; 170(10):1535-1537.
  97. Yusuf Y, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factor associated with myocardial infarction in 52 countries (The INTERHEART Study): case-control study. Lancet. 2004; 354:937-952.
  98. Grodstein F, Stampfer M. the epidemiology of coronary heart disease and estrogen replacement in post menopausal women. Prog cardiovascular dis. 1995;38:199-210.
  99. Barret-Connor E, Grady D. Hormone replacement therapy , heart disease and other consideration. Am Rev. Public Health. 1998; 9:55-72.
  100. The ESPRIT Group. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet. 2002; 360:2001-2008.
  101. Waters D, Alderman E, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women JAMA. 2002; 288(19):2432-2440.
  102. Hodis W, Mack W, Azen S, et al. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med. 2003; 349:535-545.
  103. Hodis H, Mack W, Lobo R, et al. Estrogen in the prevention of atherosclerosis. A randomized, doble bind, placebo controlled trial. Ann Intern Med. 2001; 135:939-953.
  104. Espeland MA, Applegate WB, Furberg Cd, et al. Estrogen replacement therapy and progression of intimae- medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol 1995; 142:1011-1019.
  105. Mack WJ, Slater CS, Xian M, et al. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril. 2004; 82(2):391-397.
  106. Herrington D, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the heart and estrogen/progestin replacement study. Circulation. 2002; 105: 2962-2967.
  107. Manson JE, Hsia J, Jhonson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349:523-534.
  108. Simon JA, HSIA J, Cauley J, et al. Postmenopausal hormone therapy and risk of stroke. The heart and estrogen – progestin replacement study (HERS) Circulation. 2001; 103:638-642.
  109. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking and cardiovascular, morbidity in women over 50: The Framinghan Study. N Engl J Med. 1985; 313:1038-1043.
  110. Viscoli C, Brass L, Kernan W, et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N. Engl J Med. 2001; 345(17):1243-1249.
  111. Smith GD, Shipley MJ, Rose G. Intermittent claudicating, heart disease risk factors, and mortality. The Whitehall Study. Circulation. 1990; 82:1925-1931.
  112. Hsia J, Simon J, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease. Circulation. 2000; 102:2228-2232.
  113. Karas R. Current Controversies regarding the cardiovascular effects of hormone therapy. Clinical Obstetrics and gynecology. 2004; 47 (2):489–499.
  114. Cushman M, Kuller LH, Prentice R, et al Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004; 292:1573-1580.
  115. Scarabin P, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
  116. Rosensen RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular events reduction. JAMA. 1998; 279:1643-1650.
  117. Speroff J. Clinical gynecology endocrinology and infertility. 6° ed. Lippincott. Williams & Wilkins. 1999.
  118. Collaborative Group on Hormonal Factors in Breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of date from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet 1997; 350:1047-1059.
  119. Gapstur SM,Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cacner with a favorable histology: results of the Iowa Women´s Health Study. JAMA. 1999; 281:2091-2097.
  120. Magnusson C, Baron JA, Correia N, et al. Breast cancer risk following long term estrogen and estrogen progestin replacement therapy. Int J. Cancer.1999; 81:339-344.
  121. million Women Study Collaborators. Breast cancer and hormone replacement therapy in the million women study. Lancet. 2003; 362:419-427.
  122. Beral V, Banks E, Reeves g. Evidence from randomized trials on the long term effects of hormone replacement therapy. Lancet. 2002; 360:942-944.
  123. Bundred N, Turner L. Postmenopausal hormone therapy before and after breast cancer: clinical experiences. Maturitas. 2004; 49:S22-S31.
  124. Scharier C, Lubin J, Troisis R, et al. Menopausal estrogen and estrogen – progestin replacement therapy and breast cancer risk. JAMA. 2000; 283:485-491.
  125. Colditz G, Rosner B. Nurses Health Study Research Group. Use of estrogens plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 1998; 147(suppl):64S-72S.
  126. Ross RK, Paganini Hill A, Wan PC. Effects of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000; 92:328-332.
  127. Magnusson C, Person I, Adami HO. More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl Cancer Inst. 2000; 92:1183-1184.
  128. Newcomb P, Titus-Emstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk: Cancer Epidemiol Biomarker Prev. 2002; 11:593- 600.
  129. Endogenous Hormones Breast Cancer Collaborative Group. Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women J. Ntl Cancer Inst 2003; 95:1218-1226.
  130. Chlebowski RT, Hendris SL, Langer RS, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women´s Health Initiative Randomized trial. JAMA. 2003; 289:3243-3253.
  131. Valdivia I, Campodonico I, Tapia A, et al. Effects of Tibolone and continuous combined hormone therapy on mammography breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004; 81(3):617-623.
  132. De Lignieres B, Vathaire D, Fournier S, et al Terapia combinada de reemplazo hormonal y riesgo de cáncer de mama en un estudio de grupo francés de 3175 mujeres. (versión en español). Climacteric.2002; 5:332-340.
  133. Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy. J Fam Practice 2002; 51:1056-1062.
  134. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?) a randomized comparison: trial stopped. Lancet. 2004; 363:453-455.
  135. Veronesi U, Maisonnevre P, costa A, et al. Prevention of breast cancer with Tamoxifen: preliminary findings from the Italian randomized trial among hysterectomies women. Lancet 1998; 352:93-97.
  136. Geist SHSF. The therapeutic use of amniotin in the menopause. Am J Obstet Gynecol. 1932; 23:697 – 707.
  137. Albright F. Studies on ovarian dysfunction. III. Menopause. Endocrinology. 1936; 20:24-29.
  138. Anderson AB, Sklovsky E, Sayers L, et al. comparison of serum estrogen concentrations in post-menopausal women taking estrogen sulphate and estradiol. BMJ. 1978; 1:140-142.
  139. Ramachandran C, Fleisher D. Transdermal delivery of drugs for the treatment of bone disease. Adv Drug Deliv Rev. 2000; 42:197-223.
  140. Jensen J, Christiansen C. effects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. Am J. Obstet Gynecol. 1988; 159:820-825.
  141. Dóren M, Schenider HP. Estrogen Progestogen replacement therapy in postmenopausal women is 1 mg extradiolvalerate sufficient to maintain axial trabecular bone density?. Int J Clinical Pharmacology therapy. 1994: 32(5):254-258.
  142. Ettinger E, Genant H, Steiger P, et al. Low-dose micronized 17 beta estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol. 1992; 166:479-488.
  143. Menopausal management: The impact of low dose HRT. A supplement to Contemporary OB/GYN. Julio 2001. www.contemporaryobgyn.net
  144. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause. 1999; 6(3):273-276.
  145. Mattsson L, Sporrong T. Low dose hormone replacement therapy: clinical efficacy. Minerva Ginecol. 2003; 55(3):201-207.
  146. Crandal C. Low dose estrogen therapy for menopausal women: a review of efficacy and safety. J Women’s Health 2003; 12(8):723-747.
  147. Notelovitz M, Lenihan JP, Mcdermott M, et al. Initial 17b-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000; 95:726-731.
  148. Castelo-Branco C, Colodrón M. Terapia hormonal sustitutiva a bajas dosis. Clin Invest Gin Obstet 2004; 31(5):161-168.
  149. Nilsson KE, Heimer GM. Ultra-low-dose transdermal estrogen therapy in postmenopausal urogenital estrogen deficiency-a-placebo controlled study. Menopause. 1994; 1:191-197.
  150. Grady D. Postmenopausal Hormones therapy for Symptoms only. N Engl J Med. 2003; 348: 19-21.
  151. Cushing K, Weiss N, Voigt L, et al. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogen. Obstet Gynecol 1998; 91(1):35-39.
  152. Duursma S, Raadt M, Raymakers J, et al. Is 1 mg of estradiol valerate or 0.625 mg of conjugated estrogens sufficient for all women to prevent menopausal bone loss? Gynecol Endocrinol 1992; 6:205-209.
  153. Consensus Development conference. Prophylaxis and treatment of osteoporosis. Am J Med. 1991; 90:107-110.
  154. Melton LJ, Atkinson EJ, O¨fallon WM, et al Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993; 8:1227-1273.
  155. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium. Ann Inter Med. 1987; 106:40-45.
  156. Recker R, Davies M, Dowd R, et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized controlled trial. Ann Intern Med. 1999; 130:897-904.
  157. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low dose continuous combined conjugated estrogens and medroxiprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001; 185:1180-1185.
  158. Prestwood K, Kenny AM, Kleppinger A, et al. Ultra-low dose micronized 17 estradiol and bone density and bone metabolism in older women a randomized controlled trial. JAMA. 2003; 290:1042-1048.
  159. Goeretziehner G. The role of progestagens in hormone replacement. Drug of today. 2001; 37(suppl):1-8.
  160. Schindler A, Campagnoli c, Druckmann R, et al. Classification and pharmacology of progestin’s. Maturitas. 2003; 46(suppl-1):S7-S-16.
  161. Skouby S. The rationale for a wider range of Progestogens. Climacteric. 2000; 3(2suppl): 14-20.
  162. Stanczyk F. Pharmacokinetics and potency of progestin used for hormone replacement therapy and contraception. Reviews in endocrine & metabolic disorders 2002; 3:211-224.
  163. Schneider HP. The role of antiandrogens in hormone replacement therapy. Climacteric 2000: 3(suppl2):21-27.
  164. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules risk and benefits. Menopause. 2002; 9(1):6-15.
  165. Sitruk-Ware R. Progestin’s in hormonal replacement therapy and prevention of endometrial disease. IN: Sitruk-Ware R, Mishel Dr. Progestin’s and antiprogestins in clinical practice. New York. 2000; 269-287.
  166. Monterrosa A. Anticoncepción hormonal endouterina EN: Sociedad Colombiana de Obstetricia y Ginecología (Ed.) Texto de Obstetricia y Ginecología. 2004. Bogotá.
  167. Suvanto-Lukkonen E, Malinen H, Sundstrom H, et al. Endometrial morphology during hormonal replacement therapy with estradiol gel combined to levonorgestrel releasing intrauterine device or natural progesterone. Act Obstet Gynecol Scand. 1998; 77:758-763
  168. Al-Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of uterine bleeding in sequential trimegestona-based hormone replacement therapy: a dose-ranging study. Hum Reprod. 1999; 14(3):636-641.
  169. Grubb G, Spielmann D, Pickar J, et al. Clinical experience with trimegestona as a new progestin in HRT. Steroid. 2003; 68:921-926.
  170. Mewissen J, Beijers-De bie L, Vihtamaki T, et al. A 1 year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestona. Gynecol endocrinol 2001; 15:349-358.
  171. Meuwissen J, Beijers-De Bie L, Vihtamaki T, et al. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestona. Gynecol Endocrinol. 2002; 16:155-162.
  172. Al-Azawi F, Wahab M, Thonson J, et al. Acceptability and patterns of endometrial bleeding in estradiol- based HRT regimens: a comparative study of cyclical sequential combinations of trimegestona or norethisterone acetate. Climacteric. 2001; 4:343-354.
  173. Warming L, Ravn P, Spielman D, et al. Trimegestone in a low-dose, continuous – combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause. 2004: 11(3): 337- 342.
  174. Okon M, Lee S, Laird S et al. a prospective randomized controlled study comparing two doses of gestodene in cyclic combined HRT preparations on endometrial physiology. Hum Reprod. 2001; 16(6):1244-1250.
  175. Bjarnason N, Byrjalsen I, Hassager C, et al. Low dose of estradiol in combination with gestodene to prevent early postmenopausal bone loss. Am J Obstet Gynecol. 2000; 183:550-560.
  176. Rueda C, Palacio S. Fitoéstrogenos: estado actual. Rev Col Menopausia. 2003; 9(1): 23-30.
  177. Morabito N, Crisafulli A, Vergara C, et al. Effects of genesis and hormone replacement therapy on bone loss in early postmenopausal women: a randomized double blind placebo controlled study. J Bone Miner Res. 2002; 17:1904-1912.
  178. Vincet A, Fitzpatrick LA. Soy Isoflavonas: are they useful in menopause? Mayo Clin Proc 2000; 75:1174-1184.
  179. Germain A, Peterson C, Robinson J, et al. Isoflavone rich or isoflavone poor protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause. 2001; 8: 17-26.
  180. Smith CL, O´malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine reviews. 2004; 25(1):45-71.
  181. Fisher B, Costantino JP; Wickerham L, et al. Tamoxifen for the prevention of breast cancer report of the National surgical Adjuvant breast and bowel project Study. J Natl Cancer Inst. 1998; 90:1371-1388.
  182. Cummings SR, Eckert S, Kruger KA, et al. The effects of raloxifeno on risk of breast cancer in postmenopausal women. Results from the MORE Randomized Trial. JAMA. 1999; 281:2189-2197
  183. Neven P, Lunden T, Benedetti-Paccini P, et al. a multicentre randomized trial to compare the uterine effects of raloxifeno, with a continuous combined hormone replacement therapy: result from Eurolox. Gynecological Endocrinology. 2000; 14(suppl2): 76-78.
  184. Caudley JA, Norton I, Lippman M, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifeno. Four year results from the MORE trial. Breast cancer Research and treatment. 2001; 65:125-134.
  185. Barret-Connor G, Grady D, Sashegyl A. et al. Raloxifeno and cardiovascular events in osteoporotic postmenopausal women. Four year results from the MORE randomized trial. JAMA. 2002; 287:847-857.
  186. Ettinger B, Black DM, Mitlak BC, et al. Reduction of vertebral fracture risk in postmenopausal:. Women with osteoporosis treated with Raloxifeno. Results from a 3 year-randomizados Clinical Trial. JAMA, 1999; 282:637-645.
  187. Delmas PD, Bjarnson MH, et al. Effects of Raloxifene on bone mineral density, serum cholesterol concentration and uterine endometrium in postmenopausal women. N Engl J Med. 1997; 337:1641-1647.
  188. Mosca L,Barret-Connor E, Wenger N, et al. Design and Methods of the Raloxifeno Use for the Heart (RUTH) Study. Am J Cardiol. 2001; 88:392-395.
  189. Speroff L, Clarkson TB. Is Tibolone a viable alternative to HT? Con OB/GYN. 2003;48(8):54-68.
  190. Berendsen H. Hypothesis: the role of serotonin in hot flushes. Maturitas 2000; 36:155-164.
  191. Vitale C, Fini M, Leonardo F, et al. Effects of estradiol valerato alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease. Maturitas 2001; 40:239-245.
  192. Pastore LM, Carter RA, Hulka BS, et al. Self-reported urogenital symptoms in postmenopausal women: Women´s Health Initiative. Maturitas; 2004:49:292-303
  193. US Preventive Service TASK force. Screening for osteoporosis in postmenopausal women. Ann. Intern Med 2002; 137:526-528.
  194. Paganini-Hill A. Estrogen replacement therapy – something to smile about. Compend Contin Educ Dent. Suppl 1998: S4-S8.
  195. Angerer P, Stork S, Kothny W, et al. Effects of oral postmenopausal hormone replacement on progestin of atherosclerosis. A randomized, controlled trial. Arterioscler Thromb Vasc Biol. 2001; 21:262-268.
  196. Rymer J, Wilson R, Ballard K. Making decision about hormone replacement therapy. BMJ. 2003; 326:322-326.
  197. Chlebowski RT. Menopausal hormone therapy after breast cancer. Lancet. 2004; published on line February 3, https://imagen.thelancet.com/extras/04cmt17web.pdf.
  198. López- Jaramillo P, Díaz LA, Pardo A, et al. Estrogen Therapy increases plasma concentrations of nitric oxide metabolites in postmenopausal women but increases flow mediated vasodilation only in younger women. Fertil Steril 2004; 82(6):1550-1555.
  199. Salpeter S, Wañsh J, Greyber E. et al. Mortality associated with hormone replacement therapy in younger and older women. J Gen Intern Med. 2004;19:791-804.
Anterior Siguiente

CLIC AQUÍ Y DÉJANOS TU COMENTARIO

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *